Discover
XLO
Xilio Therapeutics, Inc.
9.18
1 x 9.03
1 x 9.20
bid
ask
-
0.02
0.22%
1 @ 04:00 PM
9.18 +0.00 (0.00%)
| Ytd | 2.46% | |
| 1y | -3.57% |
9.01
day range
9.19
6.47
52 week range
12.74
| Open | 9.01 | Prev Close | 9.20 | Low | 9.01 | High | 9.19 | Mkt Cap | 60.36M |
| Vol | 6.02K | Avg Vol | 47.76K | EPS | -1.62 | P/E | -5.67 | Forward P/E | -1.91 |
| Beta | -0.20 | Short Ratio | 0.42 | Inst. Own | 29.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.79 | 200-d Avg | 8.88 | 1yr Est | 4.50 |
| Income Statement | |||
| Total Revenue | 12.65M | ||
| Revenues (USD) | 12.65M | ||
| Gross Profit | 12.65M | ||
| Operating Expenses | 26.76M | ||
| Research and Development Expense | 19.83M | ||
| Selling, General and Administrative Expense | 6.93M | ||
| Operating Income | -14.11M | ||
| Net Income | -9.53M | ||
| Net Income Common Stock | -9.53M | ||
| Net Income Common Stock (USD) | -9.53M | ||
| Consolidated Income | -9.53M | ||
| Earnings per Basic Share | -0.58 | ||
| Earnings per Basic Share (USD) | -0.58 | ||
| Earnings per Diluted Share | -0.58 | ||
| Earning Before Interest & Taxes (EBIT) | -9.53M | ||
| Earning Before Interest & Taxes (USD) | -9.53M | ||
| Weighted Average Shares | 16.35M | ||
| Weighted Average Shares Diluted | 16.35M | ||
| Balance Sheet | |||
| Cash and Equivalents | 152.15M | ||
| Cash and Equivalents (USD) | 152.15M | ||
| Current Assets | 154.21M | ||
| Property, Plant & Equipment Net | 7.47M | ||
| Total Assets | 163.49M | ||
| Debt Current | 1.38M | ||
| Total Debt | 6.64M | ||
| Current Liabilities | 42.96M | ||
| Debt Non-Current | 5.25M | ||
| Total Liabilities | 90.94M | ||
| Accumulated Retained Earnings (Deficit) | -428.32M | ||
| Shareholders Equity | 72.55M | ||
| Shareholders Equity (USD) | 72.55M | ||
| Assets Non-Current | 9.28M | ||
| Total Debt (USD) | 6.64M | ||
| Deferred Revenue | 48.01M | ||
| Liabilities Non-Current | 47.98M | ||
| Trade and Non-Trade Payables | 1.06M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 344.00K | ||
| Net Cash Flow from Financing | 35.71M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 12.81M | ||
| Capital Expenditure | -556.00K | ||
| Issuance (Purchase) of Equity Shares | 37.26M | ||
| Net Cash Flow from Investing | -556.00K | ||
| Net Cash Flow from Operations | -22.34M | ||
| Share Based Compensation | 2.21M | ||